샘플 요청 목록

 카트 문의
시장보고서
상품코드
1757974

세계의 항혈전약 시장

Antithrombotic Drugs
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 282 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 항혈전약 시장은 2030년까지 759억 달러에 달할 전망

2024년에 514억 달러로 추정된 세계의 항혈전약 시장은 분석 기간인 2024-2030년에 CAGR 6.7%로 성장하며, 2030년에는 759억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 경구 루트는 CAGR 8.1%를 기록하며, 분석 기간 종료시에는 495억 달러에 달할 것으로 예상됩니다. 주사제 루트 부문의 성장률은 분석 기간 중 CAGR 4.4%로 추정됩니다.

미국 시장은 140억 달러로 추정, 중국은 CAGR 10.8%로 성장 예측

미국의 항혈전약 시장은 2024년에 140억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 160억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 10.8%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 3.2%와 6.6%로 예측됩니다. 유럽에서는 독일이 CAGR 4.4%로 성장할 것으로 예측됩니다.

세계의 항혈전약 시장 - 주요 동향과 촉진요인 정리

항혈전제가 심혈관 및 혈전성 질환의 현대적 관리에 필수적인 이유는 무엇인가?

항혈전제는 특히 혈전색전증의 예방과 치료에 있으며, 현대 의학에서 없어서는 안 될 필수 요소입니다. 항응고제, 항혈소판제, 항혈소판제, 선용제 등 항혈전제는 심방세동, 심부정맥혈전증(DVT), 폐색전증, 고관절 치환술, 심장판막 이식술 등 수술을 받은 환자 등 혈전 위험이 높은 사람들의 혈전 예방에 널리 사용되고 있습니다. 전 세계에서 좌식 생활, 비만, 고혈압, 당뇨병 등으로 인한 심혈관 질환(CVD)이 증가함에 따라 효과적인 혈전증 예방에 대한 수요가 그 어느 때보다 높아지고 있습니다. 항혈전제는 심근경색, 허혈성 뇌졸중과 같은 급성 질환의 관리에도 필수적이며, 혈전의 예방과 적시 용해는 생명을 구하는 데 필수적입니다. 장기적인 2차 예방 전략에서 항혈전제의 역할은 이미 혈전 사건을 경험한 환자의 재발을 방지하는 것입니다. 또한 혈전 형성 위험에 대한 의료진과 환자의 인식이 높아짐에 따라 보다 광범위하고 적극적인 처방이 이루어지고 있습니다. 주요 의료기관의 임상 가이드라인은 현재 항혈전요법을 여러 적응증에 대한 표준 치료로 권장하고 있으며, 이는 항혈전요법의 의학적 필요성이 더욱 강화되고 있음을 의미합니다. 인구의 고령화와 동반 질환 증가로 항혈전 치료의 대상 환자군은 지속적으로 확대되고 있으며, 전 세계에서 급성기 및 만성기 의료 모델 모두에서 항혈전 치료가 중요한 역할을 하고 있음이 입증되고 있습니다.

과학적, 약학적인 발전은 항혈전 치료의 안전성과 효능을 어떻게 향상시키고 있는가?

약리학 및 약물 개발의 비약적인 발전으로 보다 안전하고 효과적이며 환자 친화적인 항혈전 요법이 발전하고 있습니다. 와파린이나 헤파린과 같은 기존 약물은 항응고 치료의 주역이었지만, 치료 범위가 좁고, 잦은 모니터링, 식단 및 약물과의 상호작용 등의 문제가 있었습니다. 이에 반해 차세대 항응고제, 특히 아픽사반, 리바록사반, 에독사반, 다비가트란과 같은 직접 경구용 항응고제(DOACs)는 이 분야에 혁명을 일으켰습니다. 이들 약물은 예측 가능한 약동학, 일정한 용량, 정기적인 혈액 검사 필요성이 감소하여 환자의 순응도와 삶의 질을 크게 향상시킵니다. 프라수그렐과 티카그렐롤과 같은 첨단 항혈소판제는 클로피도그렐과 같은 기존 약물에 비해 특정 고위험군 심혈관계 질환에서 우수한 치료 효과를 입증했습니다. 또한 응급상황이나 수술시 안전성을 높이는 가역적 약물 및 해독제 개발에도 제약연구는 점점 더 많은 노력을 기울이고 있습니다. 예를 들어 이달시주맙과 안덱사넷 알파는 현재 DOAC의 가역적 약물로 승인되어 출혈 위험에 대한 이전의 우려를 해소하고 있습니다. 나노테크놀러지과 표적 약물전달 시스템은 항혈전제의 국소화와 방출 제어를 최적화하고 전신 노출을 최소화하며 부작용을 줄이기 위해 연구되고 있습니다. 또한 약물유전체학 및 실제 데이터 분석의 발전에 힘입어 환자별 위험 프로파일에 맞춘 병용요법이 주목받고 있습니다. 이러한 과학적 발전은 치료 선택의 폭을 넓혀줄 뿐만 아니라, 보다 개인화되고 정확한 치료 프로토콜을 가능하게 하고, 임상의들이 혈전 위험 관리에 접근하는 방식을 재구성하고 있습니다.

인구 통계 및 임상 동향은 항혈전제 수요 증가를 어떻게 형성하고 있는가?

세계에서 만성질환 증가와 인구 고령화는 항혈전제 시장 형성에 매우 중요한 역할을 하고 있습니다. 노년층은 혈관의 노화, 운동 능력 저하, 심방세동 및 정맥혈전색전증과 같은 질환의 높은 유병률로 인해 혈전성 질환에 더 취약한 집단입니다. 이러한 인구통계학적 추세만으로도 예방적 및 치료적 항혈전 요법을 필요로 하는 환자군은 꾸준히 증가하고 있습니다. 또한 첨단 영상 진단, 일상적인 검진, 웨어러블 헬스 기술을 통한 심혈관 질환 발견 및 진단 증가는 항혈전제를 포함한 치료 프로토콜을 조기에 시작하는 데 기여하고 있습니다. 서유럽식 식습관과 좌식생활의 세계화로 인해 신흥 국가에서는 당뇨병, 비만, 고혈압이 급증하고 있으며, 이전에는 위험도가 낮다고 여겨졌던 지역에서도 수요가 더욱 증가하고 있습니다. 외과수술도 저침습 수술, 장기 이식, 암 치료 등 혈전 위험을 높이고 예방적 항혈전 요법을 필요로 하는 수술로 진화하고 있습니다. 예를 들어 암 치료에서 암과 관련된 혈전증은 심각한 합병증으로 인식되고 있으며, 특정 환자군에서는 항혈전 요법이 일상적으로 시행되고 있습니다. 또한 COVID-19 팬데믹으로 인해 심각한 바이러스 감염과 응고 장애의 연관성이 부각되면서 입원 환자에서 항응고제 사용이 확대되고, 기존 적응증을 넘어선 혈전 위험에 대한 인식이 높아졌습니다. 이러한 인구통계학적 요인과 임상적 요인의 융합은 항혈전제에 대한 지속적인 세계 수요를 창출하고, 의료 시스템에 항응고제 접근성을 개선하고 항응고제의 합리적인 사용을 위한 가이드라인을 최적화할 것을 촉구하고 있습니다.

항혈전제 시장의 세계 확장의 주요 촉진요인은 무엇인가?

항혈전제 시장 성장의 원동력은 의료, 기술, 규제 및 경제적 요인의 시너지 효과로 전 세계 순환기 및 혈액 의료를 재구성하고 있습니다. 가장 강력한 촉진요인 중 하나는 전 세계 사망률의 상당 부분을 차지하는 비감염성 질환, 특히 심혈관계 질환으로 전 세계 사망률의 상당 부분을 차지하는 비감염성 질환으로 전 세계 역학이 이동하고 있으며, DOAC의 개발과 보급은 기존 항응고제에 대한 보다 안전하고 편리한 대안을 제공함으로써 환자들의 순응도와 임상적 적용을 확대하고 시장 전망을 변화시키고 있습니다. 시장 전망을 바꾸어 놓았습니다. 탄탄한 임상 데이터와 신속한 승인 메커니즘을 바탕으로 한 규제 당국의 신약 승인은 여러 지역에서 시장 침투를 가속화하고 있습니다. 또한 신흥 국가의 의료 인프라가 확충됨에 따라 항혈전제를 포함한 생명 유지 약품에 대한 접근성이 확대되고 있으며, 많은 경우 정부 지원 보험 제도와 공중보건 구상에 의해 지원되고 있습니다. 출혈 위험을 낮춘 차세대 약물을 찾는 등 제약업계의 연구개발 투자는 혁신을 계속 촉진하고 있습니다. 원격의료 및 디지털 헬스 기술도 항혈전 치료 환자의 원격 모니터링을 용이하게 하고, 순응도와 안전성을 향상시키는 데 기여하고 있습니다. 심방세동 환자의 뇌졸중 예방, 수술 후 혈전 예방, 심혈관 질환의 장기 이차 예방 등 표준화된 치료 경로에 항혈전 치료를 통합하는 것도 중요한 원동력이 되고 있습니다. 학술 협력, 의사 교육 강화, 일반 대중을 대상으로 한 인식 개선 캠페인은 시장 프로파일을 더욱 향상시키고 있습니다. 이러한 시장 성장 촉진요인들이 복합적으로 작용하여 세계 항혈전제 시장은 강력하고 지속적인 성장세를 보이고 있으며, 성숙한 의료 경제권과 신흥 의료 경제권 모두에서 지속적인 확장을 보장하고 있습니다.

부문

투여 루트(경구 루트, 주사 루트), 유통 채널(병원 약국, 소매 약국, 온라인 약국)

조사 대상 기업의 예(총 48건)

  • Abbott Laboratories
  • AstraZeneca
  • Bayer AG
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Daiichi Sankyo
  • Eli Lilly and Company
  • GlaxoSmithKline(GSK)
  • Johnson & Johnson
  • Medtronic
  • Mylan(now part of Viatris)
  • Novartis
  • Pfizer
  • Roche
  • Sanofi
  • Servier
  • Shionogi & Co., Ltd.
  • Sun Pharmaceutical
  • Teva Pharmaceutical
  • UCB

AI 통합

당사는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장의 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.07.07

Global Antithrombotic Drugs Market to Reach US$75.9 Billion by 2030

The global market for Antithrombotic Drugs estimated at US$51.4 Billion in the year 2024, is expected to reach US$75.9 Billion by 2030, growing at a CAGR of 6.7% over the analysis period 2024-2030. Oral Route, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach US$49.5 Billion by the end of the analysis period. Growth in the Injectable Route segment is estimated at 4.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$14.0 Billion While China is Forecast to Grow at 10.8% CAGR

The Antithrombotic Drugs market in the U.S. is estimated at US$14.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$16.0 Billion by the year 2030 trailing a CAGR of 10.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.2% and 6.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

Global Antithrombotic Drugs Market - Key Trends & Drivers Summarized

Why Are Antithrombotic Drugs Crucial in the Modern Management of Cardiovascular and Thrombotic Disorders?

Antithrombotic drugs have become an indispensable part of contemporary medicine, particularly in the prevention and treatment of thromboembolic disorders, which are among the leading causes of morbidity and mortality worldwide. These drugs-which include anticoagulants, antiplatelet agents, and fibrinolytics-are widely used to prevent blood clots in high-risk populations such as patients with atrial fibrillation, deep vein thrombosis (DVT), pulmonary embolism, and those who have undergone surgeries like hip replacement or heart valve implantation. With the global rise in cardiovascular diseases (CVDs), driven by sedentary lifestyles, obesity, hypertension, and diabetes, the demand for effective thrombosis prevention is higher than ever. Antithrombotics are also vital in managing acute conditions such as myocardial infarction and ischemic stroke, where timely clot prevention or dissolution can be life-saving. Their role in long-term secondary prevention strategies ensures that patients who have already experienced clotting events remain protected from recurrence. Moreover, increasing awareness among both healthcare providers and patients about the risks of clot formation has led to broader and more proactive prescribing patterns. Clinical guidelines from leading health authorities now recommend antithrombotic therapy as a standard of care for numerous indications, reinforcing their medical necessity. As populations age and comorbidities become more common, the patient base eligible for antithrombotic therapy continues to expand, underscoring the drugs’ critical role in both acute and chronic care models globally.

How Are Scientific and Pharmaceutical Advances Improving the Safety and Efficacy of Antithrombotic Therapies?

Significant strides in pharmacology and drug development have led to the evolution of safer, more effective, and more patient-friendly antithrombotic therapies. While traditional agents such as warfarin and heparin have long been mainstays of anticoagulant therapy, they present challenges like narrow therapeutic windows, frequent monitoring, and dietary or drug interactions. In response, a new generation of antithrombotic drugs-particularly direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, edoxaban, and dabigatran-has revolutionized the field. These agents offer predictable pharmacokinetics, fixed dosing, and reduced need for routine blood testing, significantly improving patient adherence and quality of life. Advanced antiplatelet agents like prasugrel and ticagrelor have demonstrated superior outcomes in certain high-risk cardiovascular settings compared to older drugs like clopidogrel. Additionally, pharmaceutical research is increasingly focused on developing reversible agents and antidotes that enhance safety during emergency situations or surgeries. For example, idarucizumab and andexanet alfa are now approved as reversal agents for DOACs, addressing earlier concerns about bleeding risks. Nanotechnology and targeted drug delivery systems are being explored to optimize the localization and controlled release of antithrombotic agents, minimizing systemic exposure and reducing side effects. Furthermore, combination therapies tailored to patient-specific risk profiles are gaining attention, supported by advances in pharmacogenomics and real-world data analytics. These scientific developments are not only expanding the range of therapeutic options but are also enabling more personalized and precise treatment protocols, reshaping how clinicians approach thrombotic risk management.

How Are Demographic and Clinical Trends Shaping the Growing Demand for Antithrombotic Drugs?

The rising global burden of chronic conditions and aging populations is playing a pivotal role in shaping the antithrombotic drugs market. Older adults are significantly more susceptible to thrombotic events due to vascular aging, reduced mobility, and higher prevalence of conditions like atrial fibrillation and venous thromboembolism. This demographic trend alone has created a steadily expanding patient pool in need of both preventive and curative antithrombotic therapy. Additionally, the increased detection and diagnosis of cardiovascular diseases through advanced imaging, routine screenings, and wearable health technologies have contributed to earlier initiation of treatment protocols that include antithrombotics. The globalization of Western diets and sedentary lifestyles has led to a sharp rise in diabetes, obesity, and hypertension in emerging economies, further boosting demand in regions previously considered low-risk. Surgical practices have also evolved to include more minimally invasive procedures, organ transplants, and cancer treatments-all of which can increase thrombotic risk and require prophylactic antithrombotic therapy. In oncology, for example, cancer-associated thrombosis is now recognized as a significant complication, prompting routine antithrombotic use in certain patient populations. Furthermore, the COVID-19 pandemic highlighted the association between severe viral infections and coagulopathy, leading to wider use of anticoagulants in hospitalized patients and raising awareness of thrombotic risks beyond traditional indications. This convergence of demographic and clinical factors is creating sustained, global demand for antithrombotic drugs, compelling healthcare systems to enhance access and optimize guidelines for their rational use.

What Are the Key Drivers Behind the Global Expansion of the Antithrombotic Drugs Market?

The growth in the antithrombotic drugs market is driven by a synergy of medical, technological, regulatory, and economic factors that are reshaping cardiovascular and hematological care across the globe. One of the most powerful drivers is the global epidemiological transition toward non-communicable diseases, particularly cardiovascular disorders, which account for a significant share of global mortality. The development and widespread acceptance of DOACs have transformed the market landscape by offering safer, more convenient alternatives to traditional anticoagulants, thereby expanding both patient compliance and clinical applications. Regulatory approvals for newer agents, supported by robust clinical trial data and fast-track mechanisms, have accelerated market penetration in multiple regions. Additionally, expanded healthcare infrastructure in developing countries is enabling greater access to life-saving drugs, including antithrombotics, often supported by government-sponsored insurance programs and public health initiatives. The pharmaceutical industry’s investment in R&D, including the pursuit of next-generation agents with reduced bleeding risk, continues to fuel innovation. Telemedicine and digital health technologies are also contributing by facilitating remote monitoring of patients on antithrombotic therapy, improving adherence and safety. Another key driver is the integration of antithrombotic treatment into standardized care pathways for conditions such as stroke prevention in atrial fibrillation, postoperative thromboprophylaxis, and long-term secondary prevention of cardiovascular events. Academic collaborations, increased physician education, and heightened public awareness campaigns are further elevating the market profile. Combined, these drivers are generating strong and sustained growth in the global antithrombotic drugs market, ensuring its continued expansion across both mature and emerging healthcare economies.

SCOPE OF STUDY:

The report analyzes the Antithrombotic Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Administration Route (Oral Route, Injectable Route); Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • Abbott Laboratories
  • AstraZeneca
  • Bayer AG
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Daiichi Sankyo
  • Eli Lilly and Company
  • GlaxoSmithKline (GSK)
  • Johnson & Johnson
  • Medtronic
  • Mylan (now part of Viatris)
  • Novartis
  • Pfizer
  • Roche
  • Sanofi
  • Servier
  • Shionogi & Co., Ltd.
  • Sun Pharmaceutical
  • Teva Pharmaceutical
  • UCB

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Antithrombotic Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Burden of Cardiovascular and Thromboembolic Events Throws the Spotlight on Antithrombotics
    • Use in Stroke, DVT, PE, and Post-Operative Prevention Supports High Clinical Adoption
    • OEMs Offering Novel Oral Anticoagulants (NOACs) Improve Patient Compliance and Risk Profiles
    • Expansion of Indications Across Atrial Fibrillation and Cancer-Associated Thrombosis Drives Volume
    • OEM Innovation in Fixed-Dose, Low-Monitoring Drugs Enhances Outpatient Management
    • Growing Demand for Antiplatelet Agents in Secondary Prevention Enhances Therapeutic Breadth
    • Use of D-Dimer Testing and Diagnostic Algorithms Supports Risk Stratification and Timely Initiation
    • Focus on Rapid-Onset and Short Half-Life Drugs Address Surgical Bridging Needs
    • Use in Geriatric Populations With Polypharmacy Concerns Drives Development of Safer Alternatives
    • Growth in Extended Prophylaxis in Orthopedic and Cancer Surgery Enhances Institutional Use
    • OEM Investment in Combination Anticoagulant-Antiplatelet Regimens Expands Therapeutic Efficacy
    • Increased Digital Health Integration for Dosing Support and Monitoring Adds Patient Management Value
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Antithrombotic Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Antithrombotic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Antithrombotic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Antithrombotic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Oral Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Injectable Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Injectable Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Injectable Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Online Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Antithrombotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • JAPAN
    • Antithrombotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • CHINA
    • Antithrombotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • EUROPE
    • Antithrombotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Antithrombotic Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Antithrombotic Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Antithrombotic Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • FRANCE
    • Antithrombotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • GERMANY
    • Antithrombotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Antithrombotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Antithrombotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Antithrombotic Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Antithrombotic Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Antithrombotic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Antithrombotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • INDIA
    • Antithrombotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: India 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Antithrombotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Antithrombotic Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Antithrombotic Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Antithrombotic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Antithrombotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Antithrombotic Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Antithrombotic Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Antithrombotic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • AFRICA
    • Antithrombotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제